The ANRS CO13 HEPAVIH cohort is a French nationwide cohort sponsored by the ANRS (France REcherche Nord&sud Sida-hiv Hepatites). Data is owned by ANRS and there are also legal restrictions to share data publicly. Nonetheless, data can be accessed upon demand to the scientific committee and the ANRS which can allow a contractual access for collaboration purposes (<secretariat-clinique@anrs.fr>/<laure.esterle@u-bordeaux.fr>). Applicants will be asked to complete a Research Application Form specifying details for their planned study which will then be reviewed by the ANRS CO13 Hepavih Scientific commitee. The ANRS CO13 Hepavih cohort is keen to promote collaboration among researchers and to see our unique co-infected HIV-HCV patients database and biobank used in studies which meet our ethics and consenting process.

Background {#sec005}
==========

Hepatitis C Virus (HCV) infection is frequent in people living with Human Immunodeficiency Virus (HIV), ranging from 6.2% to 82.4% in injection drug users \[[@pone.0211286.ref001]\]. HIV/HCV co-infection leads to an increased mortality compared to HIV mono-infected patients \[[@pone.0211286.ref002], [@pone.0211286.ref003]\], and a more rapid liver disease progression \[[@pone.0211286.ref004], [@pone.0211286.ref005]\]. Liver-related mortality has been ranked first \[[@pone.0211286.ref006], [@pone.0211286.ref007]\] with a decline in more recent calendar years \[[@pone.0211286.ref008], [@pone.0211286.ref009]\]. Early administration of combination antiretroviral therapy (cART) and durable suppression of HIV replication have improved overall survival and delayed disease progression \[[@pone.0211286.ref010]--[@pone.0211286.ref012]\]. Despite cART, liver disease remains currently a leading cause of death \[[@pone.0211286.ref013]--[@pone.0211286.ref015]\], probably due to hepatic decompensation (14) and/or hepatocellular carcinoma \[[@pone.0211286.ref015]\]. In the era of direct acting antivirals (DAAs), sustained virological response (SVR) ranges from 85--100%; these high percentages have been obtained in randomized clinical trials \[[@pone.0211286.ref016], [@pone.0211286.ref017]\] as well as in real-life settings \[[@pone.0211286.ref018], [@pone.0211286.ref019]\], both HCV mono-infected and HIV/HCV co-infected patients. Nonetheless its impact on long-term disease progression needs further study.

There are several studies linking advanced fibrosis stages or cirrhosis including non-invasive markers of fibrosis with a higher risk for all-cause mortality, liver-related mortality or events \[[@pone.0211286.ref013], [@pone.0211286.ref020]--[@pone.0211286.ref022]\]. Other studies assessed factors associated including liver fibrosis stages with mortality or liver-related mortality with a focus on the effect of SVR on disease progression \[[@pone.0211286.ref023]--[@pone.0211286.ref026]\]. Some of these studies may suffer from methodological issues as they did not consider SVR as a time-dependent covariate, implicating a potential immortal time bias or an indication bias (SVR is directly linked to treatment and its indications). Furthermore, liver fibrosis stages may vary over time and can be influenced by SVR \[[@pone.0211286.ref027], [@pone.0211286.ref028]\]. In recent studies assessing the association between liver fibrosis stages and hepatocellular carcinoma, liver-related events, or end stage liver disease markers of liver fibrosis were not analyzed as time-dependent variables in their adjusted models. Some recent studies did not consider SVR at all \[[@pone.0211286.ref013], [@pone.0211286.ref021]\]. Thus, the association between liver stiffness measurements (LSM, a surrogate marker for liver fibrosis stages \[[@pone.0211286.ref029]\]) and its association with all-cause and liver-related mortality has not been fully described. In particular the effect of LSM on all-cause mortality taking SVR and its effect on LSM into account needs further study.

We assessed the effect liver stiffness measurements (and its evolution over time) with all-cause and liver-related mortality in HIV/HCV co-infected patients from the prospective French nationwide ANRS CO13 HEPAVIH cohort.

Patients and methods {#sec006}
====================

Study population {#sec007}
----------------

ANRS CO13 HEPAVIH is a French nationwide multicenter, observational cohort study of HIV/HCV co-infected patients with three inclusion phases: 2005--2008, 2011--2015, 2014--2015 \[[@pone.0211286.ref030]\]. All patients provided written consent for study participation and the ANRS CO13 HEPAVIH cohort has received approval by an Institutional Review board (CPP Ile de France III, file n°2234, ref CG/LG/CC 2005--255). Each participant agreed to participate to the ANRS CO13 Hepavih cohort by written consent. Data were prospectively collected using standardized case report forms including information on patient demographics, health-related behaviors (drug, tobacco and alcohol use), clinical diagnoses and laboratory tests on a yearly basis, or every six months if patients had cirrhosis. For this analysis, adult patients above 18 years with at least one LSM by FibroScan (FS) meeting the validity criteria (IQR/LSM≤30% and ten measurements, according to current guidelines), a detectable HCV ribonucleic acid (RNA), and at least one follow-up visit before 1^st^ October 2015 (administrative censoring) were included. LSM by FS is a non-invasive and repeatable tool that has been validated in HIV/HCV co-infected patients \[[@pone.0211286.ref029]\]. Patients entered the study at the date of the first valid FS.

Clinical outcomes {#sec008}
-----------------

The primary and secondary outcomes were all-cause mortality and liver-related mortality (death from end stage liver disease, liver cancer or complication of liver transplantation), respectively. Patient's status was ascertained by declaration of participating centers and by research of their vital status in the national death registry for patients lost-to follow-up \>24 months. Causes of death were reviewed by a validation committee. Patients were censored at their last follow-up date. For the secondary outcome, patients who died from a non-liver-related event were censored at their death date.

Liver stiffness measurement (LSM) {#sec009}
---------------------------------

FS was performed by trained operators in the participating centers. We considered only valid FS with cut-offs for LSM as described in the literature (\[2.5--7.1\], \]7.1--9.5\], \]9.5--12.5\] and \> 12.5 kPa) \[[@pone.0211286.ref031]\] or with two categories: ≤12.5 kPa versus \>12.5 kPa. LSM is evolving and therefore we considered it as a time-dependent covariate. LSM was also considered as a continuous time-dependent covariate in kPa.

Sustained virological response {#sec010}
------------------------------

SVR was defined as an undetectable HCV RNA assessed by polymerase chain reaction (PCR) six months after the end of treatment as this analysis included mainly patients treated by peg-interferon/ribavirin. We created a three-modalities variable: untreated (patients never receiving any HCV treatment), treated-SVR-negative (patients under HCV treatment and up to six months after the end of treatment), treated-SVR-positive (patients who achieved SVR six months after the end of their HCV treatment). When HCV RNA six months after treatment was detectable, patients were considered in the treated-SVR-negative category until the achievement of SVR with another HCV treatment. SVR was considered as a time-dependent covariate.

Others covariates {#sec011}
-----------------

Current and past alcohol consumption was assessed according to the patients' declaration to their physician, and classified as follows: never, past non-excessive, past excessive, current non-excessive and current excessive. "Excessive" was defined as \>21 glasses / week of alcohol for men, \>14 for women according to the World Health Organization. Tobacco and drug use were categorized as never, past or current. Mode of HIV transmission, presence of cART, Acquire immune deficiency syndrome (AIDS) stage and previous HCV treatment by peg-interferon/ribavirin before inclusion (pretreated versus naive) were also assessed from medical records. Laboratory assessments included HCV RNA, HIV RNA and CD4+ cell count as a time-dependent covariates, HCV genotype, hepatitis B serology, and serum chemistry panel. In order to avoid underestimation of metabolic disorders in HIV/HCV co-infected patients, a broad definition was used: presence of at least one of the following conditions: 1/ diabetes or antidiabetic treatment, 2/ lipodystrophy, 3/ insulin resistance with a HOMA-index \> 3.8 (34,35), 4/ metabolic syndrome \[[@pone.0211286.ref032]\].

Statistical analysis {#sec012}
--------------------

Survival analysis was conducted to determine factors associated with all-cause mortality and liver-related mortality. The time axis was age allowing for a precise adjustment on age, and being clinically more relevant than time since first valid FS (not corresponding to a particular event for the patient). Survival curves were constructed and compared across initial LSM categories (by Kaplan-Meier method and log-rank test for the primary outcome; Aalen-Johansen method and Gray test for the secondary outcome, to take into account competitive risks).

Cox proportional hazards models with delayed entry were used to study factors associated with mortality. In univariable analysis, factors were selected with a p-value \<0.25. In multivariable analysis, SVR, alcohol use, metabolic disorders, sex and LSM were forced into the model and factors associated with mortality (p-value \<0.05) were determined with a backward stepwise selection procedure among: 1/ fixed variables determined at inclusion: tobacco use, drug use, mode of HIV transmission, AIDS stage, previous HCV treatment, HCV genotype, HBs antigen; 2/ time-dependent variables: HIV RNA, CD4+ level. HCV RNA and cART were not included in the model due to collinearity with SVR and HIV RNA, respectively. Results were based on patients without missing data. For the analysis of liver-related mortality, the same strategy was applied but the model could not be adjusted for SVR as no patient who achieved SVR died from liver-related cause during follow-up.

A more comprehensive analysis using a joint model with shared random effects was performed as it allows studying more precisely the association between time-dependent LSM and all-cause mortality \[[@pone.0211286.ref033]\]. The joint model simultaneously estimated the trajectory of LSM (continuous variable in kPa) for which repeated data were available, and the risk of death, taking into account the link between LSM and occurrence of deaths, and the possible variation of LSM between two measurements. It was adjusted for time-dependent SVR, metabolic disorders, sex, CD4+ level, previous HCV treatment and alcohol use determined at inclusion. The effect of LSM on all-cause mortality was estimated through two parameters: the current value of LSM given by a single FS during follow-up, and the trajectory of LSM between two consecutive FS during follow-up. LSM was ln-transformed to satisfy the Gaussian hypothesis.

Statistical analyses were performed using SAS versions 9.3 and 9.4 (SAS Institute Inc., Cary, North Carolina) and JM package in R to estimate the joint model \[[@pone.0211286.ref034]\].

Results {#sec013}
=======

Study population {#sec014}
----------------

Of the 1,516 patients included from December 2005 to October 2015, 1,170 had at least one FS since their inclusion in the cohort, and 1,121 met the validity criterion. 1,100 patients met the study inclusion criteria but 38 were excluded for missing data on SVR (one) or absence of follow-up (n = 37). Finally, 1,062 patients were analyzed ([Fig 1](#pone.0211286.g001){ref-type="fig"}).

![Flowchart.](pone.0211286.g001){#pone.0211286.g001}

Characteristics of the study population at the time of first valid FS are shown in [Table 1](#pone.0211286.t001){ref-type="table"}. A LSM \>12.5 kPa was observed in 21.7% of the patients. In the LSM \>12.5 kPa group, patients were older, mostly men, had lower CD4+ counts, had more frequent metabolic disorders, were more often under HCV treatment at inclusion, and were more often pretreated for HCV.

10.1371/journal.pone.0211286.t001

###### Characteristics at baseline of HIV/HCV co-infected patients included in this analysis---ANRS CO13 HEPAVIH cohort.
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                                                      TOTAL                  LSM                                           
  --------------------------------------------------- ---------------------- ---------------------- ---------------------- ---------
  Age (years), median (IQR)                           45.7 (42.4--49.1)      45.3 (42.2--48.8)      47.3 (43.4--51.3)      \<0.001
  Sex, women, n (%)                                   321 (30.2)             274 (33.0)             47 (20.4)              \<0.001
  Alcohol consumption, n (%)                                                                                               0.008
   Never                                              230 (22.7)             183 (23.1)             47 (21.0)              
   past non-excessive                                 195 (19.2)             138 (17.5)             57 (25.4)              
   past excessive                                     116 (11.4)             84 (10.6)              32 (14.3)              
   current non-excessive                              384 (37.8)             318 (40.2)             66 (29.5)              
   current excessive                                  90 (8.9)               68 (8.6)               22 (9.8)               
  Tobacco consumption, n (%)                                                                                               0.118
   Never                                              127 (12.1)             106 (12.9)             21 (9.2)               
   past                                               174 (16.6)             128 (15.6)             46 (20.2)              
   current                                            746 (71.3)             585 (71.4)             161 (70.6)             
  Drug consumption, n (%)                                                                                                  \<0.001
   never                                              279 (26.6)             238 (29.0)             41 (17.9)              
   past                                               711 (67.7)             530 (64.6)             181 (79.0)             
   current                                            60 (5.7)               53 (6.5)               7 (3.1)                
  Mode of HIV transmission, n (%)                                                                                          0.036
   heterosexual                                       38 (4.0)               35 (4.8)               3 (1.4)                
   male homosexual                                    53 (5.6)               45 (6.2)               8 (3.7)                
   injection drug user                                761 (80.8)             575 (79.0)             186 (86.9)             
   other                                              90 (9.6)               73 (10.0)              17 (7.9)               
  Detectable HIV RNA, n (%)                           269 (25.3)             216 (26.0)             53 (22.9)              0.346
  CD4^+^ cell count(cells/mm^3^), median (IQR)        468.0 (330.0--667.5)   483.0 (350.0--687.0)   408.0 (254.0--598.0)   \<0.001
  Nadir of CD4+ (cells/mm^3^), median (IQR)           149.0 (69.0--245.5)    160.0 (75.0--256.0)    108.0 (50.0--209.0)    \<0.001
  Antiretroviral treatment, n (%)                     755 (76.3)             599 (76.6)             156 (75.0)             0.630
  HIV stage, n (%)                                                                                                         0.170
   A (asymptomatic)                                   187 (28.6)             150 (30.4)             37 (23.0)              
   B (symptomatic)                                    270 (41.3)             196 (39.8)             74 (46.0)              
   C (AIDS)                                           197 (30.1)             147 (29.8)             50 (31.1)              
  Time from HCV contamination (years), median (IQR)   21.0 (16.0--25.0)      21.0 (15.0--24.0)      22.0 (18.0--27.0)      0.006
  Detectable HCV RNA, n (%)                           866 (81.5)             684 (82.3)             182 (78.8)             0.222
  Current HCV treatment, n (%)                        111 (11.2)             67 (8.6)               44 (21.2)              \<0.001
  Previous HCV treatment, n (%)                       441 (41.5)             306 (36.8)             135 (58.4)             \<0.001
  HCV genotype, n (%)                                                                                                      0.323
   1, 4 or 5                                          832 (78.9)             646 (78.2)             186 (81.2)             
   2 or 3                                             223 (21.1)             180 (21.8)             43 (18.8)              
  Positive HBs antigen, n (%)                         22 (2.2)               18 (2.3)               4 (1.9)                1.000
  Presence of metabolic disorders, n (%)              609 (57.3)             457 (55.0)             152 (65.8)             0.003
  Presence of insulin resistance, n (%)               145 (13.7)             87 (10.5)              58 (25.1)              \<0.001
  Presence of diabetes, n (%)                         36 (3.4)               17 (2.1)               19 (8.2)               \<0.001
  Presence of metabolic syndrome, n (%)               151 (14.2)             106 (12.8)             45 (19.5)              0.010

IQR, Interquartile Range; HIV, Human Immunodeficiency Virus; HCV, Hepatitis C Virus; AIDS, acquired immunodeficiency syndrome;

^a^Chi-square test or Fisher test for qualitative covariates, Mann-Whitney-Wilcoxon test for quantitative covariates

Median follow-up was 4.9 years (IQR, 3.2--6.1 years). At the end of follow-up, 335 (31.5%) patients had never received an HCV treatment and, among the 727 patients treated at least once, 189 (26.0%) had achieved SVR: 141 (74.6%) after peg-interferon/ribavirin, 38 (20.1%) after telaprevir- or boceprevir-based therapy and 10 (5.3%) after DAA. Among those 189 patients, 11 (5.8%) had a LSM \> 12.5 kPa at SVR-time.

Death risk during follow-up {#sec015}
---------------------------

Overall, we observed 76 deaths ([Table 2](#pone.0211286.t002){ref-type="table"}). No liver transplantation occurred during follow-up. Cumulative incidence of all-cause mortality was 5.9% (95% confidence interval (95% CI): \[4.4--7.8\]) at the age of 50, 13.4% \[10.0--17.9\] at the age of 60 and 25.5% \[14.7--42.0\] at the age of 70. It was higher in the LSM \>12.5 kPa group than below this threshold (for example, at 50 years, 10.8% versus 4.5%, log rank test, *p*\<0.001) ([Fig 2](#pone.0211286.g002){ref-type="fig"}).

10.1371/journal.pone.0211286.t002

###### Causes of death---ANRS CO13 HEPAVIH cohort.
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  Cause of death                                                    n
  ----------------------------------------------------------------- ------------
  Overall                                                           76
  Liver-related death[\*](#t002fn001){ref-type="table-fn"}:         26 (34.2%)
   End stage liver disease[\*\*](#t002fn002){ref-type="table-fn"}   17
   HCC without end stage liver disease                              4
   Hepatocholangiocarcinoma                                         1
   Liver transplant complications                                   3
  HIV-related death:                                                10 (13.1%)
   Infectious disease                                               5
   Pulmonary hypertension                                           1
   Progressive multifocal leukoencephalopathy                       3
   Hodgkin lymphoma                                                 1
  Non-HIV and non-liver-related death:                              29 (38.2%)
   Cancer[\*\*\*](#t002fn003){ref-type="table-fn"}                  12
   Infectious disease                                               2
   Psychiatric disease                                              5
   Cardiovascular disease                                           4
   Sudden death                                                     1
   Toxic cause                                                      4
   Pulmonary fibrosis                                               1
  Undetermined                                                      11 (14.5%)

\*One patient was classified as a liver-related but the precise cause was not reported.

\*\*Three patients with end stage liver disease were reported to have hepatocellular carcinoma.

\*\*\* 5 broncho-pulmonary, 1 ovarian, 1 esophageal, 1 nasopharyngeal, 1 colon, 2 pancreatic, 1 breast cancers.

![Cumulative incidence of all-cause mortality (A) and liver related mortality (B).\
Cumulative incidence for patients with LSM ≤ 12.5 kPa (blue line) and patients with LSM \>12.5 kPa (red line); 95% confidence intervals are represented by pointed lines. Kaplan-Meier method (A) and Aalen-Johansen method (B).](pone.0211286.g002){#pone.0211286.g002}

Cumulative incidence of liver-related mortality was 1.6% \[0.9--2.7\] at the age of 50, 5.4% \[3.3--8.2\] at the age of 60 and 13.6% \[4.0--28.9\] at the age of 70. It was higher in the LSM \>12.5 kPa group than below this threshold (at 50 years, 6.8% versus 0.14%, Gray test, *p*\<0.001) ([Fig 2](#pone.0211286.g002){ref-type="fig"}).

There was no difference in all-cause mortality nor in liver-related mortality among the three low LSM categories \[2.5--7.1\],\] 7.1--9.5\],\] 9.5--12.5\] ([Fig 3](#pone.0211286.g003){ref-type="fig"}).

![Cumulative incidence of all-cause, mortality (A) and liver-related mortality (B).\
Black line: LSM \[2.5;7.1\] kPa, blue line: LSM \]7.1;9.5\] kPa, green line: LSM \]9.5;12.5\] kPa, and red line: LSM \>12.5 kPa. Kaplan-Meier method (A) and Aalen-Johansen method (B).](pone.0211286.g003){#pone.0211286.g003}

LSM and all-cause mortality {#sec016}
---------------------------

In univariable analysis, patients with LSM \>12.5 kPa at any point of follow-up had a higher risk of all-cause mortality compared to patients with LSM ≤12.5 kPa (crude HR \[cHR\] \[95% CI\] = 3.11 \[1.96--4.92\], *p*\<0.001). All-cause mortality was also more frequent in men, tobacco users and drug users. However, it was lower in ant-HCV pretreated patients and with an increased CD4+ count ([Table 3](#pone.0211286.t003){ref-type="table"}).

10.1371/journal.pone.0211286.t003

###### Crude (A) and adjusted (B) hazard ratios from a Cox proportional hazards model with delayed entry for all-cause mortality in HIV/HCV patients---ANRS CO13 HEPAVIH cohort.
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  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                         Univariable analysis (A)\   *P*       Multivariable analysis (B)[\*](#t003fn002){ref-type="table-fn"}\   *P*
                                                                         cHR \[95% CI\]                        aHR \[95% CI\]                                                     
  ---------------------------------------------------------------------- --------------------------- --------- ------------------------------------------------------------------ ---------
  LSM (t):                                                                                           \<0.001                                                                      \<0.001

   ≤12,5 kPa                                                             1                                     1                                                                  

   \>12,5 kPa                                                            3.11 \[1.96; 4.92\]                   3.35 \[2.06; 5.45\]                                                

  SVR (t)                                                                                                                                                                         0.002

   untreated                                                             1                                     1                                                                  

   treated-SVR-                                                          3.12 \[1.10; 4.02\]                   3.53 \[1.23; 5.47\]                                                

   treated-SVR+                                                          0.62 \[0.13; 2.88\]                   0.75 \[0.17;3.81\]                                                 

  Sex: women *versus* men                                                0.60 \[0.34; 1.04\]         0.070     0.71 \[0.40; 1.26\]                                                0.243

  Alcohol consumption                                                                                0.063                                                                        0.089

   Never                                                                 1                                     1                                                                  

   past non-excessive                                                    0.75 \[0.36; 1.56\]                   0.58 \[0.27; 1.23\]                                                

   past excessive                                                        0.40 \[0.14; 1.21\]                   0.31 \[0.10; 0.94\]                                                

   current non-excessive                                                 0.92 \[0.50; 1.68\]                   0.72 \[0.38; 1.38\]                                                

   current excessive                                                     1.80 \[0.87; 3.73\]                   1.22 \[0.57; 2.62\]                                                

  Tobacco consumption                                                                                0.048                                                                        0.015

   never                                                                 1                                     1                                                                  

   past                                                                  4.43 \[1.28; 15.33\]                  5.69 \[1.56; 20.78\]                                               

   current                                                               2.98 \[0.91; 9.74\]                   3.22 \[0.93; 11.09\]                                               

  Drug consumption                                                                                   0.094                                                                        0.447

   never                                                                 1                                     1                                                                  

   past                                                                  2.10 \[1.05; 4.20\]                   1.53 \[0.73; 3.17\]                                                

   current                                                               1.30 \[0.36; 4.76\]                   0.99 \[0.27; 3.69\]                                                

  Mode of HIV transmission                                                                           0.704                                                                        \-

   heterosexual                                                          1                                     \-                                                                 

   male homosexual                                                       1.28 \[0.20; 8.03\]                   \-                                                                 

   injection drug users                                                  1.71 \[0.41; 7.17\]                   \-                                                                 

   others                                                                1.02 \[0.19; 5.47\]                   \-                                                                 

  Detectable HIV viral load (t) versus undetectable HIV viral load (t)   0.73 \[0.37; 1.43\]         0.360     \-                                                                 \-

  CD4+ level (/50 cells/mm^3^) (t)                                       0.95 \[0.90; 0.99\]         0.008     1.00 \[0.95; 1.00\]                                                0.287

  Nadir of CD4+ (/50 cells/mm^3^)                                        0.96 \[0.87; 1.05\]         0.341     \-                                                                 \-

  HIV stage:                                                                                         0.950                                                                        \-

   A (asymptomatic)                                                      1                                     \-                                                                 

   B (symptomatic)                                                       1.02 \[0.54; 1.94\]                   \-                                                                 

   C (AIDS)                                                              1.11 \[0.55; 2.21\]                   \-                                                                 

  HCV genotype                                                                                       0.852                                                                        \-

   2 or 3 *versus* 1, 4 or 5                                             0.95 \[0.55; 1.64\]                   \-                                                                 

  Time from HCV contamination (/year)                                    1.02 \[0.97; 1.07\]         0.430     \-                                                                 \-

  Positive HBs antigen                                                   0.91 \[0.13; 6.63\]         0.929     \-                                                                 \-

  Presence of metabolic disorders                                        1.04 \[0.64; 1.67\]         0.886     0.92 \[0.56; 1.51\]                                                0.737

  Presence of previous anti-HCV treatment                                0.60 \[0.37; 0.99\]         0.046     0.53 \[0.32; 0.90\]                                                0.017
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

cHR, crude Hazard ratio; aHR, adjusted Hazard ratio; LSM, liver stiffness measurements; (t) indicates time-dependent covariables;

\*52 patients had missing data on alcohol and tobacco and were not included in the final model. There was no difference between analyzed and excluded patients (data not shown).

In multivariable analysis, LSM \>12.5 kPa at any time of follow-up was associated with an increased risk of all-cause mortality (adjusted HR (aHR) = 3.35 \[2.06--5.45\], p\<0.001), independently of SVR, sex, alcohol use, tobacco use, metabolic disorders and previous HCV treatment. In addition, tobacco use (aHR = 5.69 \[1.56; 20.78\] for past use versus never, 3.22 \[0.93; 11.09\] for current use versus never, p = 0.015) and previous HCV treatment (aHR = 0.53 \[0.32; 0.90\], p = 0.017) were also associated with all-cause mortality, independently of SVR and the other covariates ([Table 3](#pone.0211286.t003){ref-type="table"}).

The association of LSM with all-cause mortality was confirmed by the joint model. In the longitudinal sub-model, only SVR was associated with LSM trajectory during follow-up (Table in [S1 Table](#pone.0211286.s001){ref-type="supplementary-material"}). Furthermore, the model confirmed that an increase in LSM at a given time-point was associated with an increased risk of all-cause mortality, after adjustment for confounders and trajectory of LSM (aHR = 1.64 \[1.43--1.88\] for a 50% increase of current LSM value, *p*\<0.001). The trajectory of LSM between two measurements was not associated with all-cause mortality ([Table 4](#pone.0211286.t004){ref-type="table"}).

10.1371/journal.pone.0211286.t004

###### Adjusted hazard ratios for all-cause mortality from the survival sub-model of the joint model with shared random effects in HIV/HCV co-infected patients---ANRS CO13 HEPAVIH cohort.
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                                                                                                                                   aHR \[95% CI\][\*](#t004fn002){ref-type="table-fn"}   *P*
  -------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------- ---------
  Current value of LSM[\*\*](#t004fn003){ref-type="table-fn"} (for a 50% increase)                                                 1.64 \[1.43; 1.88\]                                   \<0.001
  Trajectory of LSM between the current measure and the previous one[\*\*](#t004fn003){ref-type="table-fn"} (for a 50% increase)   0.52 \[0.01; 56.15\]                                  0.787
  SVR (t)                                                                                                                                                                                0.006
   treated-SVR- *versus* untreated                                                                                                 2.05 \[1.15; 3.64\]                                   
   treated-SVR+ *versus* untreated                                                                                                 0.41 \[0.09; 1.84\]                                   
  Sex, women *versus* men                                                                                                          0.91 \[0.53; 1.55\]                                   0.731
  Alcohol consumption                                                                                                                                                                    0.373
   past non-excessive *versus* never                                                                                               0.87 \[0.42; 1.81\]                                   
   past excessive *versus* never                                                                                                   0.55 \[0.21; 1.46\]                                   
   current non-excessive *versus* never                                                                                            1.20 \[0.63; 2.30\]                                   
   current excessive *versus* never                                                                                                1.33 \[0.62; 2.86\]                                   
  CD4^+^ count (/50cells/mm^3^)                                                                                                    0.98 \[0.94; 1.03\]                                   0.444
  Presence of metabolic disorders                                                                                                  1.11 \[0.71; 1.75\]                                   0.645
  Presence of previous HCV treatment                                                                                               0.43 \[0.26; 0.72\]                                   0.001

aHR, adjusted Hazard ratio; LSM, liver stiffness measurements; SVR, sustained virological response; (t) indicates time-dependent covariables;

\*Model estimations are based on data from 959 patients without missing data for variables included in the model. In this subgroup, 67 all-cause deaths occurred.

\*\*All LSM available during follow-up were considered to calculate the trajectory of LSM, even those obtained after achieving SVR since the model was adjusted for SVR time-dependent covariate. Current value of LSM represented value at a time point t and the trajectory represented the evolution of LSM.

LSM and liver-related mortality {#sec017}
-------------------------------

The risk of liver-related mortality increased when LSM was \>12.5 kPa (cHR = 29.65 \[8.88--99.01\], *p*\<0.001), in case of metabolic disorders, and in drug users. It decreased for women, when the CD4+ level increased, for HCV genotype 2 or 3 patients, and for pretreated patients ([Table 5](#pone.0211286.t005){ref-type="table"}).

10.1371/journal.pone.0211286.t005

###### Crude (A) and adjusted (B) hazard ratio from a Cox proportional hazards model with delayed entry for occurrence of liver-related death in HIV/HCV co-infected patients from the HEPAVIH cohort.
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  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                               Univariable analysis (A)\   *P*       Multivariable analysis (B)[\*](#t005fn002){ref-type="table-fn"}\   *P*
                                                               cHR \[95% CI\]                        aHR \[95% CI\]                                                     
  ------------------------------------------------------------ --------------------------- --------- ------------------------------------------------------------------ ---------
  LSM (t):                                                                                 \<0.001                                                                      \<0.001

   ≤12,5 kPa                                                   1                                     1                                                                  

   \>12,5 kPa                                                  29.65 \[8.88; 99.01\]                 20.60 \[5.99; 70.78\]                                              

  Sex (women *versus* men)                                     0.09 \[0.01; 0.65\]         0.017     0.16 \[0.02; 1.22\]                                                0.077

  Alcohol consumption[\*\*](#t005fn003){ref-type="table-fn"}                               0.480                                                                        0.786

   never                                                       1                                     1                                                                  

   past non-excessive or excessive                             0.52 \[0.16; 1.74\]                   0.52 \[0.14; 1.92\]                                                

   current non-excessive                                       0.93 \[0.34; 2.57\]                   0.82 \[0.26; 2.62\]                                                

   current excessive                                           1.47 \[0.41; 5.26\]                   0.76 \[0.19; 3.07\]                                                

  Tobacco consumption[\*\*](#t005fn003){ref-type="table-fn"}                               0.317                                                                        \-

   never                                                       1                                     \-                                                                 

   past                                                        4.71 \[0.56; 39.79\]                  \-                                                                 

   current                                                     3.13 \[0.40; 24.69\]                  \-                                                                 

  Drug consumption[\*\*](#t005fn003){ref-type="table-fn"}                                  0.095                                                                        0.570

   never                                                       1                                     1                                                                  

   past or current                                             3.52 \[0.80; 15.42\]                  1.56 \[0.34; 7.13\]                                                

  Mode of HIV transmission                                                                 0.546                                                                        \-

   sexual                                                      1                                     \-                                                                 

   injection drug users                                        2.70 \[0.35; 20.92\]                  \-                                                                 

   others                                                      1.36 \[0.11; 17.19\]                  \-                                                                 

  Detectable HIV viral load (t)                                0.66 \[0.20; 2.22\]         0.503     \-                                                                 \-

  CD4+ count (/50 cells/mm^3^) (t)                             0.86 \[0.78; 0.95\]         \<0.001   0.90 \[0.82; 1.00\]                                                0.065

  Nadir of CD4+ (/50 cells/mm^3^)                              0.94 \[0.80; 1.11\]         0.473     \-                                                                 \-

  HIV stage                                                                                0.329                                                                        \-

   A (asymptomatic)                                            1                                     \-                                                                 

   B (symptomatic)                                             2.64 \[0.74; 9.42\]                   \-                                                                 

   C (AIDS)                                                    2.15 \[0.53; 8.66\]                   \-                                                                 

  HCV genotype:                                                                            0.195                                                                        0.243

   2 or 3 *versus* 1, 4 or 5                                   0.95 \[0.55; 1.64\]                   0.47 \[0.13; 1.67\]                                                

  Time from HCV contamination                                  1.00 \[0.92; 1.09\]         0.930     \-                                                                 \-

  Presence of metabolic disorders                              4.50 \[1.35; 15.00\]        0.014     3.91 \[1.12; 13.66\]                                               0.033

  Presence of previous HCV treatment                           0.38 \[0.15; 0.94\]         0.036     0.31 \[0.12; 0.85\]                                                0.017
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

cHR, crude Hazard ratio; aHR, adjusted Hazard ratio; LSM, liver stiffness measurements; HIV, Human immunodefiency virus; HCV, hepatitis C virus; AIDS, acquired immunodeficiency syndrome;

\*47 patients had missing data on alcohol and CD4+ count and were not included in the final model. (t) indicates time-dependent covariables. There was no difference between analyzed and excluded patients (data not shown).

\*\*Definition modified for the secondary outcome analysis because no event occurred in some categories of the original variables making the estimation of HRs impossible for these categories.

LSM \>12.5 kPa at any time remained associated with an increased risk of liver-related mortality (aHR = 20.60 \[5.99--70.78\], *p*\<0,001) after adjustment for sex, alcohol use, metabolic disorders, CD4+ level and previous HCV treatment. This result was not adjusted for SVR as no liver-related death occurred in the SVR group. Previous HCV treatment (aHR = 0.31 \[0.12--0.85\], *p* = 0.022) and metabolic disorders (aHR = 3.91 \[1.12--13.66\], *p* = 0.033) were also associated with liver-related mortality, after adjustment for the other variables ([Table 5](#pone.0211286.t005){ref-type="table"}).

Discussion {#sec018}
==========

In this large-scale assessment of mortality in a prospective, multicenter, observational cohort study of HIV/HCV co-infected patients, a LSM \>12.5 kPa at any time point during follow-up was associated with a 3 fold higher risk of all-cause mortality, independently of SVR and other main confounders. This association has been confirmed by joint modeling of the LSM trajectory and all-cause mortality. Furthermore, the latter analysis showed that mortality was related to an increase in the current LSM value at a given time point, and not to the trajectory of LSM. LSM was also associated with liver-related mortality after adjustment for main confounders. Nevertheless, small number of liver-related deaths hampered the adjustment for SVR and led to large confidence intervals.

Our results on LSM are concordant with previous studies \[[@pone.0211286.ref013], [@pone.0211286.ref020], [@pone.0211286.ref021], [@pone.0211286.ref035]\]. Limketkai et al found that patients with liver fibrosis stage F4 had a three fold higher risk of death than F0 patients \[[@pone.0211286.ref020]\]. Sanmartin et al also found a 3.7 fold higher risk of death for patients with advanced fibrosis (F3-F4) \[[@pone.0211286.ref035]\]. This is probably due to a greater incidence of liver-related events (liver decompensation, hepatocellular carcinoma...) in case of advanced fibrosis (25). Nonetheless, these studies did not consider SVR or were conducted as natural history studies, i.e. in the absence of any HCV treatment.

Previous HCV treatment was identified as a protective factor whatever the SVR status, which is concordant with results from Butt et al: in patients treated by peg-interferon/ribavirin, all-cause mortality was reduced by 30% to 60% according to treatment duration, when compared with untreated patients, whatever the treatment's outcome (SVR or not) \[[@pone.0211286.ref036]\]. This beneficial effect could result from liver fibrosis reduction in patients with no cirrhosis.

Treated-SVR negative patients were at higher risk of all-cause mortality, compared with untreated patients, probably linked to an indication bias (treatment was purposed to patients with bad prognosis). Moreover, no significant reduction of all-cause mortality was found in treated-SVR positive patients contrary to what has been described recently \[[@pone.0211286.ref037]\]. This could be explained in two ways: 1/ a lack of power, 2/ achieving SVR reduced the overmortality of treated patients, without reaching a protective effect.

The level of CD4+ was not associated with all-cause mortality which is in contrast to what has been found in previous studies including HIV/HCV co-infected patients \[[@pone.0211286.ref020], [@pone.0211286.ref037]\]. This could be explained in three ways: 1/ CD4+ level was a time-dependent covariate which could have modified its association, 2/ the principal causes of mortality in our population are non-HIV and non- liver-related deaths, 3/ most patients had recovered their immunovirological function before inclusion. Nevertheless, the association between CD4+ level and liver-related mortality almost reached statistical significance with an aHR close to the result reported by Grint et al \[[@pone.0211286.ref008]\].

No association was found between alcohol use and all-cause or liver-related mortality in our study, probably due to the low proportion of excessive alcohol consumers (90 patients, 8.9%). Furthermore, alcohol use was declared by the patient to his physician which might result in an under-reporting (social desirability bias) considering that HCV-infected patients are often aware of the seriousness of excessive alcohol use.

Our study has some limitations. First, the proportion of patients with SVR was low and only few patients were treated by DAA. Even though the SVR rate in our study did not represent the current context of HIV/ HCV co-infected patients, we do not expect that SVR modifies the effect of LSM on all-cause mortality. Indeed, a decrease of LSM values after SVR has been shown, but we would expect that higher LSM markers would still be associated with higher risk of mortality in those with and without SVR. Thus, we do not think that higher SVR rates would have led to different results.

Second, analyses were based on patient records without missing data for variables included in the final models. No imputation procedure was performed because of the small number of patients excluded for missing data and the absence of difference compared to excluded patients. Finally, the main analysis was not adjusted for hepatitis B virus (HBV) status but HBV co-infection was only present in 2.2% of the patients and all were receiving an anti-HBV active cART.

Nonetheless, our study has also several strengths. In the absence of post-SVR cohorts with sufficient follow-up, our approach allows to better understand factors associated with mortality independently of SVR and our primary results were confirmed in several sensitivity analyses. Furthermore, we used an innovative statistical approach to better characterize the association between LSM and all-cause mortality using a joint model. Finally, the interest of our results for clinical practice is important: all HIV/HCV co-infected patients, even those who achieved SVR, have to benefit from a long-term follow-up with LSM to detect patients at high mortality risk.

In conclusion, LSM \>12.5 kPa at any point in time was strongly associated with all-cause mortality independently of SVR in HIV/HCV co-infected patients. Close follow-up of these patients should remain a priority even after obtaining SVR. Post-SVR cohorts will be critical in the near future to assess the residual risk especially of liver disease progression and its associated factors. This information is of utmost importance to optimize care especially after the use of DAA.
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